Metformin therapy associated with survival benefit in lung cancer patients with diabetes

The purpose of this study is to summarize the currently available evidence regarding the concerned issue by performing a comprehensive meta-analysis. Relevant publications reporting the association of metformin use with survival of lung cancer patients with diabetes were electronically searched to identify eligible studies. The meta-analysis was performed with hazard ratios (HRs) and 95% confidence intervals (95% CIs) as effect measures for disease-free survival(DFS) and overall survival(OS) estimates. A total of 17 individual studies from 10 publications were included in the meta-analysis. Overall, the results revealed a significant association of metformin use with a better survival of lung cancer patients with diabetes(for DFS: HR = 0.65, 95% CI = 0.52-0.83; for OS: HR = 0.78, 95% CI = 0.64-0.93). The subgroup analyses showed similar association in Asian region(for DFS: HR = 0.69, 95% CI = 0.59-0.80; for OS: HR = 0.55, 95% CI = 0.46-0.67) but not in Western region. Such association was also presented in small cell lung cancer (for DFS: HR = 0.54, 95% CI = 0.38-0.77; for OS: HR = 0.52, 95% CI = 0.39-0.69) and in non-small cell lung cancer(for DFS: HR = 0.70, 95% CI = 0.51-0.96; for OS: HR = 0.75, 95% CI = 0.58-0.97). Analyses stratified by treatment strategy showed a reduction in the risk of cancer-related mortality in patients receiving chemotherapy(for DFS: HR = 0.71, 95% CI = 0.64-0.83; for OS: HR = 0.58, 95% CI = 0.47-0.71) but not in patients receiving chemoradiotherapy. The meta-analysis demonstrated that metformin use was significantly associated with a favorable survival outcome of lung cancer patients with diabetes.